Evidence map›Paper›PMID 35992109›Full record

ArticleFrontiers in endocrinology2022

Alternation between toxic and proliferative effects of Roundup® on human thyroid cells at different concentrations.

Izabela Fernanda Dal' Bó, Elisângela Souza Teixeira, Larissa Teodoro Rabi, Karina Colombera Peres, Matheus Nascimento, Maria Izabel Chiamolera, Valdemar Máximo, Natássia Elena Bufalo, Laura Sterian Ward

Open access · goldAbstract read
In one paragraph

Article in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. RoundupFrontiers in endocrinology · 2026
    Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Izabela Fernanda Dal' BóLaboratory of Cancer Molecular Genetics, School of Medical Sciences, University of Campinas, Campinas, Brazil.
Elisângela Souza TeixeiraLaboratory of Cancer Molecular Genetics, School of Medical Sciences, University of Campinas, Campinas, Brazil.
Larissa Teodoro RabiLaboratory of Cancer Molecular Genetics, School of Medical Sciences, University of Campinas, Campinas, Brazil.
Karina Colombera PeresLaboratory of Cancer Molecular Genetics, School of Medical Sciences, University of Campinas, Campinas, Brazil.
Matheus NascimentoLaboratory of Cancer Molecular Genetics, School of Medical Sciences, University of Campinas, Campinas, Brazil.
Maria Izabel ChiamoleraSão Leopoldo Mandic School of Medicine, Campinas, Brazil.
Valdemar MáximoDepartment of Medicine, Federal University of São Paulo, São Paulo, Brazil.
Natássia Elena BufaloLaboratory of Cancer Molecular Genetics, School of Medical Sciences, University of Campinas, Campinas, Brazil.
Laura Sterian WardLaboratory of Cancer Molecular Genetics, School of Medical Sciences, University of Campinas, Campinas, Brazil.
Universidade Estadual de Campinas (UNICAMP) · BRFaculdade São Leopoldo Mandic · BRUniversidade do Porto · PTUniversidade Federal de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endocrine-disrupting and carcinogenic effects of glyphosate have long been suspected, but little is known about the effect of compounds used in real life at different concentrations, neither in normal nor in thyroid tumor cells. As cancer cells may have different sensitivities and the effect of the product containing glyphosate may be different from that produced by the active ingredient alone, including the Acceptable Occupational Exposure Level (AOEL=160µg/L) and the Acceptable Daily Intake (ADI=830µg/L) determined by ANVISA, we used two human thyroid-derived cell lines, Nthy-ori 3-1 (from normal follicular cells) and TPC-1 (from papillary carcinoma), to test 15 different concentrations of Roundup® Original DI. Trypan blue (TB), CCK-8 and BrdU assays were used to evaluate cytotoxicity, metabolic activity and proliferation with 24h and 48h exposures in technical and biological triplicates. TB showed an important toxic effect, especially after 24h of exposure, in both cell lines. The AOEL concentration caused the death of 43% and 50% of the Nthy-ori and TPC-1 cells, respectively, in 24 h, while ADI resulted in 35% and 58% of cell death. After 48h of exposure, AOEL and ADI caused a lower number of dead Nthy-ori (33% and 18%) and TPC-1 (33% and 37%) cells, respectively, suggesting that the toxic effect of the product disappears and/or both strains have repair mechanisms that protect them from longer exposures. On the other hand, the CCK-8 assay showed that small concentrations of Roundup have a proliferative effect: 6.5µg/L increased the number of both Nthy-ori and TPC-1 cells at 24h, and the BrdU assay confirmed the stimulatory effect with a 321% increase in the absorbance of Nthy-ori cells at 48h. The herbicide produced even more frequent increases in the BrdU absorbance of TPC-1 cells, mainly at 24h. We conclude that thyroid cells exposed to Roundup present a nonmonotonic dual dose-response curve. Low concentrations of the pesticide, considered acceptable, cause significant cell death but also have an important proliferative effect, especially on TPC-1 cells. This herbicide, widely used around the world, may play a role in the increased incidence rate of thyroid nodules and cancer that has been observed in recent decades.

Indexed as

Carcinoma, PapillaryHerbicidesBromodeoxyuridineHumansThyroid GlandBromodeoxyuridineHerbicidescytotoxicityendocrine disruptorglyphosatepesticideproliferationthyroid

Identifiers

PMID35992109
PMCPMC9382701
OpenAlexW4288425274

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.